Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Operating Leases: 2023-2024

Historic Operating Leases for Centessa Pharmaceuticals (CNTA) over the last 2 years, with Dec 2024 value amounting to $8.3 million.

  • Centessa Pharmaceuticals' Operating Leases fell 6.40% to $8.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.4 million, marking a year-over-year decrease of 6.40%. This contributed to the annual value of $8.3 million for FY2024, which is 6.77% down from last year.
  • As of FY2024, Centessa Pharmaceuticals' Operating Leases stood at $8.3 million, which was down 6.77% from $8.9 million recorded in FY2023.
  • Centessa Pharmaceuticals' 5-year Operating Leases high stood at $8.9 million for FY2023, and its period low was $8.3 million during FY2024.
  • Over the past 2 years, Centessa Pharmaceuticals' median Operating Leases value was $8.6 million (recorded in 2023), while the average stood at $8.6 million.
  • Data for Centessa Pharmaceuticals' Operating Leases shows a maximum YoY decreased of 6.77% (in 2024) over the last 5 years.
  • Yearly analysis of 2 years shows Centessa Pharmaceuticals' Operating Leases stood at $8.9 million in 2023, then decreased by 6.77% to $8.3 million in 2024.